Search
Now showing items 1-10 of 14
Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.
(NATURE PORTFOLIO, 2022-04-28)
In estrogen-receptor-positive, HER2-negative (ER+HER2-) breast cancer, higher levels of tumor infiltrating lymphocytes (TILs) are often associated with a poor prognosis and this phenomenon is still poorly understood. ...
TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial
(AMER ASSOC CANCER RESEARCH, 2015-05-01)
DECONVOLVING CONVOLUTIONAL NEURAL NETWORK FOR CELL DETECTION
(IEEE, 2019-01-01)
NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL
(FERRATA STORTI FOUNDATION, 2016-06-01)
Short-term presurgical treatment for all?
(BIOMED CENTRAL LTD, 2007-01-01)
THE TEN-YEAR EVOLUTIONARY TRAJECTORY OF A HIGHLY RECURRENT PAEDIATRIC HIGH GRADE NEUROEPITHELIAL TUMOUR WITH MN1:BEND2 FUSION
(OXFORD UNIV PRESS INC, 2018-06-01)
PARP inhibitors and breast cancer: highlights and hang-ups
(TAYLOR & FRANCIS LTD, 2018-01-01)
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).
(SAGE PUBLICATIONS LTD, 2020-12-01)
BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor ...
Anal squamous cell carcinoma in a high HIV prevalence population.
(SPRINGER, 2021-02-11)
Anal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of ...